Buyback yield (TTM)
0.02%
Shareholder yield (TTM)
0.02%
5Y share count change
12.8%
Buyback spend (TTM)
$167.00K
Cumulative buybacks
$167.00K
Key takeaways
- Alto Neuroscience (ANRO) repurchased about $167.00K of stock over the trailing twelve months.
- Diluted share count is up 12.8% over the last ~5 fiscal years — equity issuance and stock-based compensation are outpacing repurchases.
- TTM buyback ÷ stock-based-comp ratio of 0.04× — repurchases only partially offset SBC dilution.
Dividend & buyback yield over time for Alto Neuroscience (ANRO)
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Diluted vs basic shares (annual) for Alto Neuroscience (ANRO)
Diluted weighted-average shares are the EPS denominator — a falling count means buybacks are outpacing SBC dilution.
Year-over-year change in diluted shares for Alto Neuroscience (ANRO)
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Cash buyback spend over time for Alto Neuroscience (ANRO)
Latest: $167.00K
Overview
In 2025, Alto Neuroscience (ANRO) buyback spend totalled $167.00K.
Across the available history, buyback spend reached its high of $167.00K in 2025 and its low of $0.00 in 2021.
Alto Neuroscience Buyback Spend 2025: $167.00K
Alto Neuroscience buyback spend in 2025 was $167.00K.
Alto Neuroscience Buyback Spend 2024: $0.00
Alto Neuroscience buyback spend in 2024 was $0.00.
Alto Neuroscience Buyback Spend 2023: $0.00
Alto Neuroscience buyback spend in 2023 was $0.00.
Alto Neuroscience Buyback Spend 2022: $0.00
Alto Neuroscience buyback spend in 2022 was $0.00.
Alto Neuroscience Buyback Spend 2021: $0.00
Alto Neuroscience buyback spend in 2021 was $0.00.
See more financial history for Alto Neuroscience (ANRO).
Buyback, SBC & dilution history
Buyback spend, SBC, net dilution effect, and share count.
| 2025 | $167.00K | $8.11M | −$7.94M | 0.03% | 0.03B | +17.3% | |
| 2024 | $0.00 | $7.63M | −$7.63M | — | 0.02B | -8.5% | |
| 2023 | $0.00 | $2.89M | −$2.89M | — | 0.03B | +5.1% | |
| 2022 | $0.00 | $1.76M | −$1.76M | — | 0.03B | 0.0% | |
| 2021 | $0.00 | $227.00K | −$227.00K | — | 0.03B | — |
- 2025$167.00K
- 2024$0.00
- 2023$0.00
- 2022$0.00
- 2021$0.00
Buybacks vs stock-based compensation for Alto Neuroscience (ANRO)
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 0.04×.
Buybacks vs dividends (share of cash returned) for Alto Neuroscience (ANRO)
How Alto Neuroscience splits cash returned to shareholders between dividends and buybacks.
Sector peers by buyback spend
Companies in the same sector as Alto Neuroscience, ranked by their latest buyback spend.
| $5.95B | |
| $5.54B | |
| $5.08B | |
| $4.11B | |
| $980.00M | |
| $719.66M | |
| $216.35M | |
| $0.00 |
- $5.95B
- $5.54B
- $5.08B
- $4.11B
- $980.00M
- $719.66M
- $216.35M
- $0.00
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $0.00 (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Data & methodology
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation